ElectroCore Is Changing the Game in Bioelectronics

electroCore, a player in the bioelectronic’s market is on a mission to redefine the way patients are treated for migraines. The Basking Ridge, N.J.-based company recently launched the gammaCore Sapphire, a second-generation device that is non-invasive vagus nerve stimulator for the acute treatment of pain associated with migraine and episodic cluster headache. The gammaCore Sapphire was cleared in December of 2017 but electroCore delayed the product’s launch. “We were waiting to launch the gammaCore Sapphire after we launched into migraine, which happened on July 1 of this year,” Frank Amato, CEO of electroCore, told MD+DI. “We were trying to time both our broad commercial launch across the U.S. in migraine with the new second-generation device.” The proceeds from electroCore’s IPO were used to help fund the launch of the product. The handheld device is self-administered by patients and is placed on the neck over the vagus nerve. Amato noted if you can find your pulse on either side of your trachea then you can find where the vagus nerve is. Once the fibers of the vagus nerve are stimulated with the device, it reduces or relieves pain for the patient. “The first-generation device, gammaCore is a product that requires the patients to get a new device each month,” Amato said. “With the sec...
Source: MDDI - Category: Medical Devices Authors: Tags: Digital Health Source Type: news